SPT — Investor Presentation 2021

May 26, 2021

1789 TT

ScinoPharm

May 26, 2021

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The information contained in this presentation is ScinoPharm’s confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty , express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to , the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. These forward-looking statements involve known and unknown risks , uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.

2

==> picture [82 x 26] intentionally omitted <==

Table of Content

 Company Overview

 Business Update

 Financial Performance

3

==> picture [720 x 88] intentionally omitted <==

Company Overview

4

ScinoPharm at a Glance

• Est. in 1997 in Taiwan (Tainan) with cGMP plants/R&D in Tainan

and Changshu and marketing forces in Tainan, Shanghai and Tokyo  Specializes in high potency (cytotoxic/steroid) API and injectable R&D and manufacturing with customers worldwide

• 74 generic APIs in portfolio with 32 referred and approved by ANDA/NDA*

• 872 active DMFs worldwide with 64 US DMFs

• 150+ contract projects with 7 approved/launched (5 NCEs) and 8 in phase 3 for NDA/MAA filing in 1-3 years*

 Certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority

• Data as of 2021/04/30

5

==> picture [720 x 88] intentionally omitted <==

Business Update

6

Business Strategies

==> picture [234 x 220] intentionally omitted <==

----- Start of picture text -----

專注發展
Advancing to
高附加價值
Injectables
針劑產品
----- End of picture text -----

==> picture [234 x 219] intentionally omitted <==

----- Start of picture text -----

擴張
Expand CDMO
“新藥代客研製”
Business
服務
----- End of picture text -----

==> picture [233 x 220] intentionally omitted <==

----- Start of picture text -----

Optimize
Existing Generic
API Portfolio
----- End of picture text -----

==> picture [695 x 179] intentionally omitted <==

----- Start of picture text -----

積極開發日本、中國與新興市場
Actively Develop Japan, China and Emerging Markets
----- End of picture text -----

7

==> picture [161 x 150] intentionally omitted <==

----- Start of picture text -----

Optimize
Existing
Generic API
Portfolio
----- End of picture text -----

 Generic API Business

 Leverage Tainan / Changshu production advantage with better sales / production coordination to stabilize supply  The impact of Covid-19 pandemic  Existing Generic API Portfolio

==> picture [498 x 238] intentionally omitted <==

----- Start of picture text -----

38
40 Data as of 2021/04/30
35
Pipeline
30 Approved
20
25
20
12
15
10 18 7 6 6
5 4 2 3 2 2 2 2 1
5 2 4 3 2 1 1 2 2 1
0
----- End of picture text -----

==> picture [35 x 33] intentionally omitted <==

==> picture [378 x 58] intentionally omitted <==

8

==> picture [161 x 150] intentionally omitted <==

----- Start of picture text -----

Optimize
Existing
Generic API
Portfolio
----- End of picture text -----

 2021 Generic API Product A roval Plan pp

Type	Product	Region	Indication	Brand Marketer
Generic API	Fondaparinux Sodium	CN( )	Anti-thrombotic	Mylan
Generic API	Irinotecan HCl	CN	Colorectal cancer	Pfizer
Generic API	Anastrozole	CN	Breast cancer	ANI Pharmaceuticals
Generic API	Sodium Phenylbutyrate	CN( )	Urea cycle disorders	Horizon Therapeutics
Generic API	Azilsartan	CN	Hypertension	Arbor Pharmaceuticals
Generic API	Letrozole	CN	Breast cancer	Novartis
Generic API	Bimatoprost	CN	Glaucoma	Allergan
Generic API	Regadenoaon	US	MPI	Astellas
Generic API	＊Pemetrexed Disodium 7H2O CEP	EU	Non-small cell lung cancer	Eli Lilly
Generic API	Topiramate	EU	Weight management	Vivus

：Approved ＊： Collaborative project for drug product development Data as of 2021/04/30

9

==> picture [161 x 151] intentionally omitted <==

----- Start of picture text -----

Expand
CDMO
Business
----- End of picture text -----

 CDMO Business

==> picture [514 x 346] intentionally omitted <==

----- Start of picture text -----

13
14
11
12
10
7
8
6 7
8
1 SciAnda (Changshu)
ScinoPharm Taiwan
6
4
7 7
6
5
2
0
Phase 1 Phase 2 Phase 3 Commercial
----- End of picture text -----

Data as of 2021/04/30

10

Expand CDMO Business	2021 CDMO API Product Approval Plan	2021 CDMO API Product Approval Plan	2021 CDMO API Product Approval Plan	2021 CDMO API Product Approval Plan	2021 CDMO API Product Approval Plan
	Type	Product	Region	Indication	Brand Marketer
	CDMO API	Donafenib	CN	Cancer	Suzhou Zelgen
	CDMO API	Leuprolide Mesylate	US/EU	Cancer	Foresee
	CDMO API	Eflornithine	US/EU	FAP	CPP
	Data as of 2021/04/30

 Donafenib, customer’s NCE application, expected to be approved in China in May, 2021  2 CDMO products submitted to EMA and FDA by customers; one is expected to receive FDA response in mid-2021

11

==> picture [161 x 151] intentionally omitted <==

----- Start of picture text -----

Advancing
to
Injectables
----- End of picture text -----

==> picture [127 x 100] intentionally omitted <==

Peptides

==> picture [132 x 114] intentionally omitted <==

==> picture [134 x 114] intentionally omitted <==

Sterile Injectables Pen Injectors

• Profit-sharing from 3 drug products (in-house development + outsourcing production)

• ANDA of 1[st] in-house prefilled-syringe product was submitted to FDA in May, 2020 – Response to FDA in progress

• Registration batches of Vial line (prefilled-syringed /pen device) and Cartridge line (liquid solution/ lyophilized powder) products were completed

• Completed the 1[st] TFDA on-site inspection in Apr. 2021, pending for official inspection report

• Target to submit the 2[nd] in-house produced ANDA in Q2, 2021 and

• 1[st] NDA (505(b)(2)) in Q4, 2021

12

==> picture [678 x 101] intentionally omitted <==

----- Start of picture text -----

Actively Develop Japan, China and Emerging Markets
----- End of picture text -----

Japan Market

• Japan office will upgrade to a branch to facilitate business

• The impact of Covid-19 pandemic

• The largest generic API supplier for Galantamine HBr and Capecitabine in Japan

• Indication： Alzheimer’s disease / Various cancers

• ：

• Japan market size c. USD 200 million / over USD 100 million

 Leverage Japan’s late patent expiration and our new injectables capacity to explore opportunities for generic APIs + CDMO projects

13

China Market

• Customer’s Fondaparinux Sodium PFS launched in Feb. 2021

• Indication：Anti-thrombotic

• Market Size：c. RMB 200 million

• Changshu site completed CFDI’s 1[st] on-site inspection for Sodium Phenylbutyrate in Sep. 2020. Customer obtained approval in May, 2021 and will launch in China as orphan drug  Indication： Urea cycle disorders

• Changshu site, in Feb. 2021, completed CFDI’s on-site inspection for NCE - Donafenib

• Customer approval expected in May, 2021

  • Indication：Advanced liver cancer first-line treatment

  • 1[st] ：c. RMB 220 year sales projected by research report

  • million

• Changshu site to activate another 3 on-site inspections in 2021

14

==> picture [720 x 88] intentionally omitted <==

Financial Performance

15

Consolidated Income Statement

In NTD Million, except for EPS	1Q 2021 (Reviewed)	1Q 2021 (Reviewed)	YoY	1Q 2020 (Reviewed)	1Q 2020 (Reviewed)
Revenue	641	100%	18%	543	100%
Gross Profit	365	57%	49%	244	45%
Operating Profit	110	17%	147%	45	8%
Net Profit before Tax	113	18%	131%	49	9%
Net Profit after Tax	90	14%	155%	35	7%
EPS (NTD)	0.11	-	-	0.04	-

16

1Q 2021 Sales Distribution

==> picture [674 x 225] intentionally omitted <==

----- Start of picture text -----

Drug India China Others
CDMO
Product Japan 3% 9% 9%
19%
6% 11%
US+Canada
Generic 28%
EU
API
40%
75%
CNS Others
by Business
21% 7% by Region
----- End of picture text -----

by Indication

17

Sales Distribution – YoY

B Business Unit: USD y Generic API CDMO Drug Product 1Q 2021 Sales 17.0M 4.3M 1.3M YoY 4.8% 178.9% 669.3%

B Business y

B Indication y

Oncology CNS Others 1Q 2021 Sales 16.3M 4.6M 1.7M YoY 22.7% 38.4% 24.5%

By Region

US & EU Japan India China Others Canada 1Q 2021 Sales 9.1M 6.4M 2.5M 0.6M 2.0M 2.0M YoY 5.5% 80.9% -28.3% 78.2% 545.1% 21.1%

18

Consolidated Balance Sheet

In NTD Million	2021/3/31 (Reviewed)	2021/3/31 (Reviewed)	2020/3/31 (Reviewed)	2020/3/31 (Reviewed)
Cash and Cash Equivalents	4,040	33%	3,691	32%
Accounts Receivable	321	3%	398	3%
Inventories	1,423	12%	1,276	11%
Property, Plant & Equipment	4,164	34%	4,351	37%
Other Current/Non-Current Assets	2,230	18%	1,936	17%
Total Assets	12,178	100%	11,652	100%
Financial Debt	43	0%	232	2%
Other Current Liabilities	696	6%	575	5%
Other Non-Current Liabilities	628	5%	706	6%
Total Liabilities	1,367	11%	1,513	13%
Total Shareholders' Equities	10,811	89%	10,139	87%

19

Consolidated Cash Flow Statement

==> picture [634 x 396] intentionally omitted <==

----- Start of picture text -----

1Q 2021 1Q 2020
In NTD million
(Reviewed) (Reviewed)
From Operating Activities 117 264
From Investing Activities (162) 144
From Financing Activities 31 (3)
Effect of foreign exchange rate changes (1) (19)
Net Change in Cash (15) 386
Beginning Balance 4,055 3,305
Ending Balance 4,040 3,691
----- End of picture text -----

20

==> picture [720 x 88] intentionally omitted <==

Q & A

21

==> picture [81 x 27] intentionally omitted <==

==> picture [676 x 127] intentionally omitted <==

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT

22